QM · rank #15 · 2026-07-22
SNT
GPW · PLN · $841M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +52.14% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $841M |
| Anchor (recent) Close on 2026-06-22 | $307.00 |
| Anchor (far) Close on 2025-06-20 | $201.78 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. manufactures proprietary radiopharmaceuticals and distributes high-end medical imaging and therapeutic systems, including da Vinci surgical robots, across Central Europe.
Rationale
The quality-momentum signal is validated by strong price momentum and exceptional return on equity, supported by strong order visibility with a recent 112 million PLN quarterly order intake and expanding recurring revenues.
Material risks
- 1Loss of single-source exclusive distribution rights for high-margin systems like da Vinci or the newly certified Edison platform would severely impair its core revenue engine.
- 2The trailing 55% ROE signal is temporarily distorted by a massive 261.3 million PLN one-off gain on the Syn2bio spin-off, overstating the profitability of its continuing operations.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.